Hide metadata

dc.contributor.authorStuen, Hanne K
dc.contributor.authorLandheim, Anne
dc.contributor.authorRugkåsa, Jorun
dc.contributor.authorWynn, Rolf
dc.date.accessioned2018-09-25T05:02:16Z
dc.date.available2018-09-25T05:02:16Z
dc.date.issued2018
dc.identifier.citationInternational Journal of Mental Health Systems. 2018 Sep 22;12(1):51
dc.identifier.urihttp://hdl.handle.net/10852/64925
dc.description.abstractBackground The first 12 Norwegian assertive community treatment (ACT) teams were piloted from 2009 to 2011. Of the 338 patients included during the teams’ first year of operation, 38% were subject to community treatment orders (CTOs). In Norway as in many other Western countries, the use of CTOs is relatively high despite lack of robust evidence for their effectiveness. The purpose of the present study was to explore how responsible clinicians reason and make decisions about the continued use of CTOs, recall to hospital and the discontinuation of CTOs within an ACT setting. Methods Semi-structured interviews with eight responsible clinicians combined with patient case files and observations of treatment planning meetings. The data were analysed using a modified grounded theory approach. Results The participants emphasized that being part of a multidisciplinary team with shared caseload responsibility that provides intensive services over long periods of time allowed for more nuanced assessments and more flexible treatment solutions on CTOs. The treatment criterion was typically used to justify the need for CTO. There was substantial variation in the responsible clinicians’ legal interpretation of dangerousness, and some clinicians applied the dangerousness criterion more than others. Conclusions According to the clinicians, many patients subject to CTOs were referred from hospitals and high security facilities, and decisions regarding the continuation of CTOs typically involved multiple and interacting risk factors. While patients’ need for treatment was most often applied to justify the need for CTOs, in some cases the use of CTOs was described as a tool to contain dangerousness and prevent harm.
dc.language.isoeng
dc.rightsThe Author(s); licensee BioMed Central Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleHow clinicians make decisions about CTOs in ACT: a qualitative study
dc.typeJournal article
dc.date.updated2018-09-25T05:02:17Z
dc.creator.authorStuen, Hanne K
dc.creator.authorLandheim, Anne
dc.creator.authorRugkåsa, Jorun
dc.creator.authorWynn, Rolf
dc.identifier.cristin1609868
dc.identifier.doihttps://doi.org/10.1186/s13033-018-0230-2
dc.identifier.urnURN:NBN:no-67461
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/64925/1/13033_2018_Article_230.pdf
dc.type.versionPublishedVersion
cristin.articleid51


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International